Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Scola, P.M., Wang, A.X., Good, A.C., Sun, L.Q., Combrink, K.D., Campbell, J.A., Chen, J., Tu, Y., Sin, N., Venables, B.L., Sit, S.Y., Chen, Y., Cocuzza, A., Bilder, D.M., D'Andrea, S., Zheng, B., Hewawasam, P., Ding, M., Thuring, J., Li, J., Hernandez, D., Yu, F., Falk, P., Zhai, G., Sheaffer, A.K., Chen, C., Lee, M.S., Barry, D., Knipe, J.O., Li, W., Han, Y.H., Jenkins, S., Gesenberg, C., Gao, Q., Sinz, M.W., Santone, K.S., Zvyaga, T., Rajamani, R., Klei, H.E., Colonno, R.J., Grasela, D.M., Hughes, E., Chien, C., Adams, S., Levesque, P.C., Li, D., Zhu, J., Meanwell, N.A., McPhee, F.
J.Med.Chem.
